Michael Bromley

This study develops an ex vivo porcine corneal model to evaluate combined natamycin and PACK-CXL treatment for fungal keratitis, showing it reduces fungal burden more effectively than either treatment alone.

This paper quantifies gene gain and loss dynamics in Aspergillus fumigatus over a century using a global pangenome, revealing slow genome evolution and lineage-specific resistance mechanisms.

The paper identifies genes involved in sulfur metabolism in Aspergillus fumigatus during infection, highlighting ShmB as a promising antifungal target due to its essential role in virulence and structural differences from the human enzyme.

This study identifies a mutation rate increase in a multi-azole resistant Aspergillus fumigatus clade, linking it to rapid antifungal resistance evolution.

This study identifies a specific stage of Aspergillus fumigatus spore development that activates dendritic cells to trigger allergic airway inflammation and shows antifungal drugs can reduce this process.

The paper investigates the regulatory motifs in the cyp51A promoter of Aspergillus fumigatus that contribute to azole resistance, revealing iron-dependent and -independent roles of transcription factors.

The paper uses population genomics to trace the evolution and environmental acquisition of drug-resistant Aspergillus fumigatus, finding evidence of resistant isolates transmitted from the environment to patients.